INSTITUT DE FORMULATION DES VACCINS (CH) SA

INSTITUT DE FORMULATION DES VACCINS (CH) SA specializes in the discovery and advanced development of novel vaccine adjuvants, with a focus on liposome-based saponin-containing formulations for next-generation pandemic preparedness. The contractor leverages cutting-edge biotechnological research to design and optimize immune-enhancing compounds, particularly for pan-sarbecovirus vaccines, integrating molecular design, formulation science, and preclinical validation. Complementing this, they apply computer systems design services to support complex bioinformatics workflows, including data modeling, simulation environments, and digital infrastructure for adjuvant development pipelines. Their technical differentiation lies in the integration of computational design with experimental immunology to accelerate the transition from candidate identification to functional formulation. The contractor maintains a consistent partnership with the Department of Health and Human Services, delivering high-impact R&D services focused on vaccine innovation and biotechnological advancement. Their work for HHS centers on targeted adjuvant discovery and the digital systems required to manage and analyze multi-omics data in support of vaccine design. This sustained engagement suggests a trusted role in federal efforts to strengthen pandemic response capabilities through novel immunological platforms. Their primary industry focus is in biotechnology research and development, specifically in non-nanobiotech vaccine adjuvant innovation, positioning them at the intersection of immunology, pharmaceutical formulation, and computational biology. They serve the public health biodefense and vaccine development market, with expertise in delivery systems that enhance antigen presentation and T-cell activation. As an 8H entity based in Plan-les-Ouates, Switzerland, the contractor operates as a specialized research-focused firm without federal certifications. Their geographic presence supports international collaboration with U.S. federal agencies, leveraging Swiss expertise in pharmaceutical innovation to address global health security priorities.